<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39338380</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>From the "One-Molecule, One-Target, One-Disease" Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1218</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph17091218</ELocationID><Abstract><AbstractText>Non-polio enteroviruses (NPEVs), namely coxsackieviruses (CV), echoviruses (E), enteroviruses (EV), and rhinoviruses (RV), are responsible for a wide variety of illnesses. Some infections can progress to life-threatening conditions in children or immunocompromised patients. To date, no treatments have been approved. Several molecules have been evaluated through clinical trials without success. To overcome these failures, the multi-target directed ligand (MTDL) strategy could be applied to tackle enterovirus infections. This work analyzes registered clinical trials involving antiviral drugs to highlight the best candidates and develops filters to apply to a selection for MTDL synthesis. We explicitly stated the methods used to answer the question: which solution can fight NPEVs effectively? We note the originality and relevance of this proposal in relation to the state of the art in the enterovirus-inhibitors field. Several combinations are possible to broaden the antiviral spectrum and potency. We discuss data related to the virus and data related to each LEAD compound identified so far. Overall, this study proposes a perspective on different strategies to overcome issues identified in clinical trials and evaluate the "MTDL" potential to improve the efficacy of drugs, broaden the antiviral targets, possibly reduce the adverse effects, drug design costs and limit the selection of drug-resistant virus variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roux</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Aix-Marseille Université, CNRS, ICR UMR_7273, LPCR, Faculté de Pharmacie, 13005 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touret</LastName><ForeName>Franck</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4734-2249</Identifier><AffiliationInfo><Affiliation>Unité des Virus Émergents (UVE: Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA), 13005 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathelot</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2132-5862</Identifier><AffiliationInfo><Affiliation>Aix-Marseille Université, CNRS, ICR UMR_7273, LPCR, Faculté de Pharmacie, 13005 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanelle</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9946-829X</Identifier><AffiliationInfo><Affiliation>Aix-Marseille Université, CNRS, ICR UMR_7273, LPCR, Faculté de Pharmacie, 13005 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roche</LastName><ForeName>Manon</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9892-9173</Identifier><AffiliationInfo><Affiliation>Aix-Marseille Université, CNRS, ICR UMR_7273, LPCR, Faculté de Pharmacie, 13005 Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">combination</Keyword><Keyword MajorTopicYN="N">drug design</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">multi-target directed ligand</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39338380</ArticleId><ArticleId IdType="pmc">PMC11434921</ArticleId><ArticleId IdType="doi">10.3390/ph17091218</ArticleId><ArticleId IdType="pii">ph17091218</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peigue-Lafeuille H. Picornaviridae. In: Estem Edition, editor. Traité de Virologie Médicale. 1st ed. SFM; Paris, France: 2003. pp. 389–405.</Citation></Reference><Reference><Citation>Palmer P., Lebon P. Entérovirus. In: Médecine Sciences Edition, editor. Les Virus Transmissibles de la Mère à L’enfant. 1st ed. La Librairie Médicale, Scientifique &amp; Technique; Arcueil, France: 1999. pp. 305–318.</Citation></Reference><Reference><Citation>Pons-Salort M., Parker E.P., Grassly N.C. The Epidemiology of non-polio enteroviruses: Recent advances and outstanding questions. Curr. Opin. Infect. Dis. 2015;28:479–487. doi: 10.1097/QCO.0000000000000187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000187</ArticleId><ArticleId IdType="pmc">PMC6624138</ArticleId><ArticleId IdType="pubmed">26203854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy H., Poelman R., Knoester M., Van Leer-Buter C.C., Niesters H.G.M. Enterovirus D68—The New polio? Front. Microbiol. 2018;9:2677. doi: 10.3389/fmicb.2018.02677.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02677</ArticleId><ArticleId IdType="pmc">PMC6243117</ArticleId><ArticleId IdType="pubmed">30483226</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens D.M., Folkers G.K., Fauci A.S. Acute flaccid myelitis: Something old and something new. mBio. 2019;10:10–1128. doi: 10.1128/mBio.00521-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00521-19</ArticleId><ArticleId IdType="pmc">PMC6445942</ArticleId><ArticleId IdType="pubmed">30940708</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D.M., Zhang Y., Scheuermann R.H. Epidemiology and sequence-based evolutionary analysis of circulating non-polio enteroviruses. Microorganisms. 2020;8:1856. doi: 10.3390/microorganisms8121856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8121856</ArticleId><ArticleId IdType="pmc">PMC7759938</ArticleId><ArticleId IdType="pubmed">33255654</ArticleId></ArticleIdList></Reference><Reference><Citation>Haston J.C., Dixon T.C. Nonpolio enterovirus infections in neonates. Pediatr. Ann. 2015;44:e103–e107. doi: 10.3928/00904481-20150512-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/00904481-20150512-09</ArticleId><ArticleId IdType="pubmed">25996196</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Tijsma A., Mirabelli C., Baggen J., Wahedi M., Franco D., De Palma A., Leyssen P., Verbeken E., van Kuppeveld F.J.M., et al. Intra-Host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence. Emerg. Microbes. Infect. 2019;8:1076–1085. doi: 10.1080/22221751.2019.1644142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2019.1644142</ArticleId><ArticleId IdType="pmc">PMC6711088</ArticleId><ArticleId IdType="pubmed">31339457</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. 2015;60:797–803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins P.G. Enteroviral conjunctivitis and its neurological complications. Arch. Virol. 1982;73:91–101. doi: 10.1007/BF01314718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01314718</ArticleId><ArticleId IdType="pubmed">6293412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D., Krogstad P. Enteroviruses in the early 21st century: New manifestations and challenges. Curr. Opin. Pediatr. 2016;28:107–113. doi: 10.1097/MOP.0000000000000303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000303</ArticleId><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Disease Outbreak News (7th of June 2023) from World Health Organization Site.  [(accessed on 4 July 2024)].  Available online:  https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON474.</Citation></Reference><Reference><Citation>Messacar K., Abzug M.J., Dominguez S.R. The Emergence of enterovirus-D68. Microbiol. Spectr. 2016;4:105–119. doi: 10.1128/microbiolspec.EI10-0018-2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.EI10-0018-2016</ArticleId><ArticleId IdType="pubmed">27337448</ArticleId></ArticleIdList></Reference><Reference><Citation>Benschop K.S., Albert J., Anton A., Andrés C., Aranzamendi M., Armannsdóttir B., Bailly J.L., Baldanti F., Baldvinsdóttir G.E., Beard S., et al. Re-Emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021. Euro. Surveill. 2021;26:2100998. doi: 10.2807/1560-7917.ES.2021.26.45.2100998.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.45.2100998</ArticleId><ArticleId IdType="pmc">PMC8646978</ArticleId><ArticleId IdType="pubmed">34763750</ArticleId></ArticleIdList></Reference><Reference><Citation>To K.K.W., Yip C.C.Y., Yuen K.Y. Rhinovirus—From Bench to bedside. J. Formos. Med. Assoc. 2017;116:496–504. doi: 10.1016/j.jfma.2017.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2017.04.009</ArticleId><ArticleId IdType="pubmed">28495415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljubin-Sternak S., Meštrović T., Ivković-Jureković I., Kolarić B., Slović A., Forčić D., Tot T., Mijač M., Vraneš J. The Emerging role of rhinoviruses in lower respiratory tract infections in children—Clinical and molecular epidemiological study from Croatia, 2017–2019. Front. Microbiol. 2019;10:2737. doi: 10.3389/fmicb.2019.02737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02737</ArticleId><ArticleId IdType="pmc">PMC6901631</ArticleId><ArticleId IdType="pubmed">31849887</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirabelli C., Scheers E., Neyts J. Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis. F1000Research. 2017;6:1860. doi: 10.12688/f1000research.11978.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.11978.1</ArticleId><ArticleId IdType="pmc">PMC5657016</ArticleId><ArticleId IdType="pubmed">29123648</ArticleId></ArticleIdList></Reference><Reference><Citation>Grozdanov P., Joffret M.L., Stoyanova A., Polston P., Achouri E., Nikolova I., Delpeyroux F., Galabov A.S. Genome analysis of coxsackievirus B1 isolates during the consecutive alternating administration course of triple antiviral combination in newborn mice. Antivir. Chem. Chemother. 2020;28:2040206620906061. doi: 10.1177/2040206620906061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206620906061</ArticleId><ArticleId IdType="pmc">PMC7013111</ArticleId><ArticleId IdType="pubmed">32041425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanko K., Shi C., Patil S., Delang L., Matthijnssens J., Mirabelli C., Neyts J. Assessing in vitro resistance development in enterovirus A71 in the context of combination antiviral treatment. ACS. Infect. Dis. 2021;7:2801–2806. doi: 10.1021/acsinfecdis.0c00872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00872</ArticleId><ArticleId IdType="pubmed">34529400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shyr Z.A., Cheng Y.S., Lo D.C., Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov. Today. 2021;26:2367–2376. doi: 10.1016/j.drudis.2021.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.05.008</ArticleId><ArticleId IdType="pmc">PMC8139175</ArticleId><ArticleId IdType="pubmed">34023496</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:391. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M.I., Zarif F., Poh C.L. Antivirals blocking entry of enteroviruses and therapeutic potential. J. Biomed. Sci. 2021;28:10. doi: 10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Nakib W., Higgins P.G., Barrow G.I., Tyrrell D.A., Andries K., Vanden Bussche G., Taylor N., Janssen P.A. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837) Antimicrob. Agents Chemother. 1989;33:522–525. doi: 10.1128/AAC.33.4.522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.33.4.522</ArticleId><ArticleId IdType="pmc">PMC172472</ArticleId><ArticleId IdType="pubmed">2543283</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner R.B., Dutko F.J., Goldstein N.H., Lockwood G., Hayden F.G. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob. Agents Chemother. 1993;37:297–300. doi: 10.1128/AAC.37.2.297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.37.2.297</ArticleId><ArticleId IdType="pmc">PMC187656</ArticleId><ArticleId IdType="pubmed">8383943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Hipskind G.J., Woerner D.H., Eisen G.F., Janssens M., Janssen P.A., Andries K. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 1995;39:290–294. doi: 10.1128/AAC.39.2.290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.39.2.290</ArticleId><ArticleId IdType="pmc">PMC162529</ArticleId><ArticleId IdType="pubmed">7726484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Andries K., Janssen P.A. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 1992;36:727–732. doi: 10.1128/AAC.36.4.727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.4.727</ArticleId><ArticleId IdType="pmc">PMC189373</ArticleId><ArticleId IdType="pubmed">1503435</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiff G.M., Sherwood J.R. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J. Infect. Dis. 2000;181:20–26. doi: 10.1086/315176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315176</ArticleId><ArticleId IdType="pubmed">10608746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart H.A., Webster A.D., Pleconaril Treatment Registry Group Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin. Infect. Dis. 2001;32:228–235. doi: 10.1086/318452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318452</ArticleId><ArticleId IdType="pubmed">11170912</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Allergy and Infectious Diseases (NIAID)  Pleconaril Enteroviral Sepsis Syndrome. A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates with Enteroviral Sepsis Syndrome. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT00031512.</Citation></Reference><Reference><Citation>Bauer S., Gottesman G., Sirota L., Litmanovitz I., Ashkenazi S., Levi I. Severe coxsackie virus B infection in preterm newborns treated with pleconaril. Eur. J. Pediatr. 2002;161:491–493. doi: 10.1007/s00431-002-0929-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-002-0929-5</ArticleId><ArticleId IdType="pubmed">12200608</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug M.J., Cloud G., Bradley J., Sánchez P.J., Romero J., Powell D., Lepow M., Mani C., Capparelli E.V., Blount S., et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr. Infect. Dis. J. 2003;22:335–341. doi: 10.1097/01.inf.0000059765.92623.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000059765.92623.70</ArticleId><ArticleId IdType="pubmed">12690273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C., Hayden F.G., Demenczuk T.M., Barone L.R., McKinlay M.A., Collett M.S. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob. Agents Chemother. 2005;49:4492–4499. doi: 10.1128/AAC.49.11.4492-4499.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.11.4492-4499.2005</ArticleId><ArticleId IdType="pmc">PMC1280128</ArticleId><ArticleId IdType="pubmed">16251287</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmond R.A., Accortt N.A., Talley L., Villano S.A., Soong S.J., Whitley R.J. Enteroviral meningitis: Natural history and outcome of pleconaril therapy. Antimicrob. Agents Chemother. 2006;50:2409–2414. doi: 10.1128/AAC.00227-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00227-06</ArticleId><ArticleId IdType="pmc">PMC1489762</ArticleId><ArticleId IdType="pubmed">16801419</ArticleId></ArticleIdList></Reference><Reference><Citation>Merck Sharp &amp; Dohme LLC  Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295). A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)]; Available online:  https://ClinicalTrials.gov/show/NCT00394914.</Citation></Reference><Reference><Citation>Biota Scientific Management Pty Ltd  A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model. EU Clinical Trials Register.  [(accessed on 4 July 2024)].  Available online:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001714-24.</Citation></Reference><Reference><Citation>Biota Scientific Management Pty Ltd  A Phase 2 Study of BTA798 in Asthmatic Adults with Symptomatic Human Rhinovirus Infection (RHINO). A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults with Symptomatic Human Rhinovirus Infection. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)]; Available online:  https://ClinicalTrials.gov/show/NCT01175226.</Citation></Reference><Reference><Citation>Biota Pharmaceuticals, Inc  A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection. EU Clinical Trials Register.  [(accessed on 4 July 2024)].  Available online:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001785-95.</Citation></Reference><Reference><Citation>Biota Pharmaceuticals, Inc  A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection. World Health Organisation, International Clinical Trias Registery Platform.  [(accessed on 4 July 2024)].  Available online:  https://trialsearch.who.int/Trial2.aspx?TrialID=NCT02367313.</Citation></Reference><Reference><Citation>Abzug M.J., Michaels M.G., Wald E., Jacobs R.F., Romero J.R., Sánchez P.J., Wilson G., Krogstad P., Storch G.A., Lawrence R., et al. A Randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J. Pediatric. Infect. Dis. Soc. 2016;5:53–62. doi: 10.1093/jpids/piv015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piv015</ArticleId><ArticleId IdType="pmc">PMC4765488</ArticleId><ArticleId IdType="pubmed">26407253</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaxart H. A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects with Symptomatic Rhinovirus Infection. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects with Symptomatic Rhinovirus Infection. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)]; Available online:  https://ClinicalTrials.gov/show/NCT03024177.</Citation></Reference><Reference><Citation>Woods M.G., Diana G.D., Rogge M.C., Otto M.J., Dutko F.J., McKinlay M.A. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 1989;33:2069–2074. doi: 10.1128/AAC.33.12.2069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.33.12.2069</ArticleId><ArticleId IdType="pmc">PMC172823</ArticleId><ArticleId IdType="pubmed">2559655</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries K., Dewindt B., Snoeks J., Willebrords R., van Eemeren K., Stokbroekx R., Janssen P.A. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 1992;36:100–107. doi: 10.1128/AAC.36.1.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.1.100</ArticleId><ArticleId IdType="pmc">PMC189235</ArticleId><ArticleId IdType="pubmed">1317142</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C., Tull T.M., Seipel M.E., Groarke J.M. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 1999;43:2109–2115. doi: 10.1128/AAC.43.9.2109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.9.2109</ArticleId><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Aradottir E., Alonso E.M., Shulman S.T. Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr. Infect. Dis. J. 2001;20:457–459. doi: 10.1097/00006454-200104000-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-200104000-00022</ArticleId><ArticleId IdType="pubmed">11332680</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson K.G., Brown R.N., Cameron R., Chalmers D.K., Hamilton S., Jin B., Krippner G.Y., Luttick A., McConnell D.B., Reece P.A., et al. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 2003;46:3181–3184. doi: 10.1021/jm0202876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0202876</ArticleId><ArticleId IdType="pubmed">12852746</ArticleId></ArticleIdList></Reference><Reference><Citation>Altesa Biosciences, Inc  RCT of Vapendavir in Patients with COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection. A Trial in Participants with Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)];2017  Available online:  https://ClinicalTrials.gov/show/NCT06149494.</Citation></Reference><Reference><Citation>Phillpotts R.J., Jones R.W., Delong D.C., Reed S.E., Wallace J., Tyrrell D.A. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981;1:1342–1344. doi: 10.1016/S0140-6736(81)92520-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(81)92520-4</ArticleId><ArticleId IdType="pubmed">6113314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Gwaltney J.M., Jr. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob. Agents Chemother. 1982;21:892–897. doi: 10.1128/AAC.21.6.892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.21.6.892</ArticleId><ArticleId IdType="pmc">PMC182041</ArticleId><ArticleId IdType="pubmed">6287928</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller F.D., Monto A.S., DeLong D.C., Exelby A., Bryan E.R., Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob. Agents Chemother. 1985;27:102–106. doi: 10.1128/AAC.27.1.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.27.1.102</ArticleId><ArticleId IdType="pmc">PMC176213</ArticleId><ArticleId IdType="pubmed">2984980</ArticleId></ArticleIdList></Reference><Reference><Citation>Levandowski R.A., Pachucki C.T., Rubenis M., Jackson G.G. Topical enviroxime against rhinovirus infection. Antimicrob. Agents Chemother. 1982;22:1004–1007. doi: 10.1128/AAC.22.6.1004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.22.6.1004</ArticleId><ArticleId IdType="pmc">PMC185710</ArticleId><ArticleId IdType="pubmed">6297380</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts R.J., Wallace J., Tyrrell D.A., Tagart V.B. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob. Agents Chemother. 1983;23:671–675. doi: 10.1128/AAC.23.5.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.23.5.671</ArticleId><ArticleId IdType="pmc">PMC184785</ArticleId><ArticleId IdType="pubmed">6870216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsyu P.H., Pithavala Y.K., Gersten M., Penning C.A., Kerr B.M. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob. Agents Chemother. 2002;46:392–397. doi: 10.1128/AAC.46.2.392-397.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.46.2.392-397.2002</ArticleId><ArticleId IdType="pmc">PMC127051</ArticleId><ArticleId IdType="pubmed">11796347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., Patick A.K., Smith G.J., 3rd, Zalman L.S. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 2003;47:3907–3916. doi: 10.1128/AAC.47.12.3907-3916.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.12.3907-3916.2003</ArticleId><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., Petersen A., Smith G.J., 3rd, Zalman L.S., Burns-Naas L.A., et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2005;49:2267–2275. doi: 10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankam M.K., Burns J.M., Collett M.S., Corrado M.L., Hincks J.R. A Phase 1 study of the safety, tolerability, and pharmacokinetics of single and multiple oral doses of V-7404 in healthy adult volunteers. Antimicrob. Agents Chemother. 2021;65:10–1128. doi: 10.1128/AAC.01029-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01029-21</ArticleId><ArticleId IdType="pmc">PMC8448163</ArticleId><ArticleId IdType="pubmed">34370575</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X., Lei X., Zhang Z., Ma Y., Qi J., Wu C., Xiao Y., Li L., He B., Wang J. Enterovirus 3A facilitates viral replication by promoting phosphatidylinositol 4-kinase IIIβ-ACBD3 Interaction. J. Virol. 2017;91:10–1128. doi: 10.1128/JVI.00791-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00791-17</ArticleId><ArticleId IdType="pmc">PMC5599760</ArticleId><ArticleId IdType="pubmed">28701404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu N.Y., Ilnytska O., Belov G., Santiana M., Chen Y.H., Takvorian P.M., Pau C., van der Schaar H., Kaushik-Basu N., Balla T., et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141:799–811. doi: 10.1016/j.cell.2010.03.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.03.050</ArticleId><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 2011;85:2364–2372. doi: 10.1128/JVI.02249-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02249-10</ArticleId><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y., Lin L., Chen Y., Wu S., Si X., Wu H., Zhai X., Wang Y., Tong L., Pan B., et al. Curcumin inhibits the replication of enterovirus 71 in vitro. Acta. Pharm. Sin. B. 2014;4:284–294. doi: 10.1016/j.apsb.2014.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2014.06.006</ArticleId><ArticleId IdType="pmc">PMC4629085</ArticleId><ArticleId IdType="pubmed">26579397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., Qian W., Liu H., Jiang H., Yan J. Enterovirus 71 and Coxsackievirus A16 3C Proteases: Binding to Rupintrivir and Their Substrates and Anti-Hand, Foot, and Mouth Disease Virus Drug Design. J. Virol. 2011;85:10319–10331. doi: 10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang F., Xia H., Wang P., Yang J., Zhao T., Zhang Q., Hu Y., Zhou X. The identification and characterization of nucleic acid chaperone activity of human enterovirus 71 nonstructural protein 3AB. Virology. 2014;464–465:353–364. doi: 10.1016/j.virol.2014.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2014.07.037</ArticleId><ArticleId IdType="pmc">PMC7112070</ArticleId><ArticleId IdType="pubmed">25113906</ArticleId></ArticleIdList></Reference><Reference><Citation>Enviroxime PubChem Page.  [(accessed on 4 July 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/enviroxime.</Citation></Reference><Reference><Citation>Sun L., Meijer A., Froeyen M., Zhang L., Thibaut H.J., Baggen J., George S., Vernachio J., van Kuppeveld F.J.M., Leyssen P., et al. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob. Agents Chemother. 2015;59:7782–7785. doi: 10.1128/AAC.01375-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01375-15</ArticleId><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau D.H., Yuan J., Zhang H., Cheung P., Lim T., Liu Z., Sall A., Yang D. Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. Apoptosis. 2007;12:513–524. doi: 10.1007/s10495-006-0013-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-006-0013-0</ArticleId><ArticleId IdType="pubmed">17195095</ArticleId></ArticleIdList></Reference><Reference><Citation>Amineva S.P., Aminev A.G., Palmenberg A.C., Gern J.E. Rhinovirus 3C protease precursors 3CD and 3CD’ localize to the nuclei of infected cells. Pt 10J. Gen. Virol. 2004;85:2969–2979. doi: 10.1099/vir.0.80164-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.80164-0</ArticleId><ArticleId IdType="pubmed">15448360</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Webber S.E., Marakovits J.T., Fuhrman S.A., Patick A.K., Matthews D.A., Lee C.A., Ford C.E., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 1999;42:1213–1224. doi: 10.1021/jm9805384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9805384</ArticleId><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Johnson T.O., Hua Y., Luu H.T., Sakata S.K., Brown E.L., Maldonado F.C., Tuntland T., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J. Med. Chem. 2003;46:4572–4585. doi: 10.1021/jm030166l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm030166l</ArticleId><ArticleId IdType="pubmed">14521419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffey M.J., Gwaltney J.M., Jr., Dressler W.E., Sorrentino J.V., Hayden F.G. Intranasally administered atropine methonitrate treatment of experimental rhinovirus colds. Am. Rev. Respir. Dis. 1987;135:241–244.</Citation><ArticleIdList><ArticleId IdType="pubmed">3800150</ArticleId></ArticleIdList></Reference><Reference><Citation>Curovir A.B. A Randomised, Double-Blind, Single-Centre, Placebo-Controlled, First-in-Human Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of CUR-N399 in Healthy Volunteers. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)]; Available online:  https://ClinicalTrials.gov/show/NCT05016687.</Citation></Reference><Reference><Citation>Winther B., Buchert D., Turner R.B., Hendley J.O., Tschaikin M. Decreased rhinovirus shedding after intranasal oxymetazoline application in adults with induced colds compared with intranasal saline. Am. J. Rhinol. Allergy. 2010;24:374–377. doi: 10.2500/ajra.2010.24.3491.</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/ajra.2010.24.3491</ArticleId><ArticleId IdType="pubmed">21244738</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson A.B., Kraus G.P. StatPearls. 1st ed. StatPearls Publishing; Saint Petersburg, FL, USA: 2024. Physiology, Cholinergic Receptors.</Citation><ArticleIdList><ArticleId IdType="pubmed">30252390</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce R.J., Allen C.J., Campbell A.H. A comparative study of atropine methonitrate, salbutamol, and their combination in airways obstruction. Thorax. 1979;34:45–50. doi: 10.1136/thx.34.1.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.34.1.45</ArticleId><ArticleId IdType="pmc">PMC471006</ArticleId><ArticleId IdType="pubmed">375461</ArticleId></ArticleIdList></Reference><Reference><Citation>Melia C.E., van der Schaar H.M., Lyoo H., Limpens R.W.A.L., Feng Q., Wahedi M., Overheul G.J., van Rij R.P., Snijder E.J., Koster A.J., et al. Escaping Host Factor PI4KB Inhibition: Enterovirus Genomic RNA Replication in the Absence of Replication Organelles. Cell Rep. 2017;21:587–599. doi: 10.1016/j.celrep.2017.09.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.068</ArticleId><ArticleId IdType="pmc">PMC5656745</ArticleId><ArticleId IdType="pubmed">29045829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong D.H.J., Yogarajah T., Wong Y.H., Arbrandt G., Westman J., Chu J.J.H. CUR-N399, a PI4KB inhibitor, for the treatment of Enterovirus A71 infection. Antivir. Res. 2023;218:105713. doi: 10.1016/j.antiviral.2023.105713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2023.105713</ArticleId><ArticleId IdType="pubmed">37657668</ArticleId></ArticleIdList></Reference><Reference><Citation>Biazi G.R., Frasson I.G., Miksza D.R., de Morais H., de Fatima Silva F., Bertolini G.L., de Souza H.M. Decreased hepatic response to glucagon, adrenergic agonists, and cAMP in glycogenolysis, gluconeogenesis, and glycolysis in tumor-bearing rats. J. Cell Biochem. 2018;119:7300–7309. doi: 10.1002/jcb.27027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.27027</ArticleId><ArticleId IdType="pubmed">29761924</ArticleId></ArticleIdList></Reference><Reference><Citation>Durkee C.A., Covelo A., Lines J., Kofuji P., Aguilar J., Araque A. Gi/o protein-coupled receptors inhibit neurons but activate astrocytes and stimulate gliotransmission. Glia. 2019;67:1076–1093. doi: 10.1002/glia.23589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23589</ArticleId><ArticleId IdType="pmc">PMC6462242</ArticleId><ArticleId IdType="pubmed">30801845</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenisch B., Walstab J., Herberhold S., Bootz F., Tschaikin M., Ramseger R., Bönisch H. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam. Clin. Pharmacol. 2010;24:729–739. doi: 10.1111/j.1472-8206.2009.00805.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1472-8206.2009.00805.x</ArticleId><ArticleId IdType="pubmed">20030735</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed S.E., Craig J.W., Tyrrell D.A. Four compounds active against rhinovirus: Comparison in vitro and in volunteers. J. Infect. Dis. 1976;133((Suppl. S2)):A128–A1235. doi: 10.1093/infdis/133.Supplement_2.A128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/133.Supplement_2.A128</ArticleId><ArticleId IdType="pubmed">180193</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts R.J., Higgins P.G., Willman J.S., Tyrrell D.A., Lenox-Smith I. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. J. Antimicrob. Chemother. 1984;14:403–409. doi: 10.1093/jac/14.4.403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/14.4.403</ArticleId><ArticleId IdType="pubmed">6094423</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerial A., Werner G.H., Phillpotts R.J., Willmann J.S., Higgins P.G., Tyrrell D.A. Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob. Agents Chemother. 1985;27:846–850. doi: 10.1128/AAC.27.5.846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.27.5.846</ArticleId><ArticleId IdType="pmc">PMC180164</ArticleId><ArticleId IdType="pubmed">2990329</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Nakib W., Higgins P.G., Barrow I., Tyrrell D.A., Lenox-Smith I., Ishitsuka H. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers. J. Antimicrob. Chemother. 1987;20:887–892. doi: 10.1093/jac/20.6.887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/20.6.887</ArticleId><ArticleId IdType="pubmed">3326874</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasin S.R., Al-Nakib W., Tyrrell D.A. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410. Antimicrob. Agents Chemother. 1990;34:963–966. doi: 10.1128/AAC.34.6.963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.34.6.963</ArticleId><ArticleId IdType="pmc">PMC171738</ArticleId><ArticleId IdType="pubmed">2168152</ArticleId></ArticleIdList></Reference><Reference><Citation>GlaxoSmithKline Research &amp; Development Limited  A Randomised, Double-Blind, Placebo Controlled, Repeat Dose Phase 1b Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled GSK3923868 during Experimental Human Rhinovirus Infection in Participants with Mild Asthma. World Health Organisation, International Clinical Trias Registery Platform.  [(accessed on 4 July 2024)].  Available online:  https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN15115094.</Citation></Reference><Reference><Citation>GlaxoSmithKline  A Randomized, Double-Blind, Placebo Controlled, Repeat Dose Phase 1b Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled GSK3923868 during Experimental Human Rhinovirus Infection in Participants with Mild Asthma. World Health Organisation, International Clinical Trias Registery Platform.  [(accessed on 4 July 2024)].  Available online:  https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05398198.</Citation></Reference><Reference><Citation>Ishitsuka H., Ninomiya Y.T., Ohsawa C., Fujiu M., Suhara Y. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrob. Agents Chemother. 1982;22:617–621. doi: 10.1128/AAC.22.4.617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.22.4.617</ArticleId><ArticleId IdType="pmc">PMC183802</ArticleId><ArticleId IdType="pubmed">6295261</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto A.J., Hall T.S., Reed S.E. Trial of the antiviral action of isoprinosine against rhinovirus infection of volunteers. Antimicrob. Agents Chemother. 1973;3:332–334. doi: 10.1128/AAC.3.3.332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.3.3.332</ArticleId><ArticleId IdType="pmc">PMC444410</ArticleId><ArticleId IdType="pubmed">4364175</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachuta D.M., Togo Y., Hornick R.B., Schwartz A.R., Tominaga S. Evaluation of isoprinosine in experimental human rhinovirus infection. Antimicrob. Agents Chemother. 1974;5:403–408. doi: 10.1128/AAC.5.4.403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.5.4.403</ArticleId><ArticleId IdType="pmc">PMC428983</ArticleId><ArticleId IdType="pubmed">15825396</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman R.H., Gangulyj R. Therapeutic efficacy of inosiplex (Isoprinosine) in rhinovirus infection. Ann. N. Y. Acad. Sci. 1977;284:153–160. doi: 10.1111/j.1749-6632.1977.tb21946.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1977.tb21946.x</ArticleId><ArticleId IdType="pubmed">81636</ArticleId></ArticleIdList></Reference><Reference><Citation>Romark Laboratories L.C. A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)]; Available online:  https://ClinicalTrials.gov/show/NCT03605862.</Citation></Reference><Reference><Citation>Romark Laboratories L.C. Phase 3, A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection. National Library of Medecine, National Center for Biotechnology Information.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT04489381.</Citation></Reference><Reference><Citation>Reed S.E., Bynoe M.L. The antiviral activity of isoquinoline drugs for rhinoviruses in vitro and in vivo. J. Med. Microbiol. 1970;3:346–352. doi: 10.1099/00222615-3-2-346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/00222615-3-2-346</ArticleId><ArticleId IdType="pubmed">4318080</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo Y., Schwartz A.R., Hornick R.B. Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection. Antimicrob. Agents Chemother. 1973;4:612–616. doi: 10.1128/AAC.4.6.612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.4.6.612</ArticleId><ArticleId IdType="pmc">PMC444606</ArticleId><ArticleId IdType="pubmed">4367686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee P.K., Esper F., Buchheit K., Arters K., Adkins I., Ghannoum M.A., Salata R.A. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect. Dis. 2017;17:74. doi: 10.1186/s12879-016-2177-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-2177-8</ArticleId><ArticleId IdType="pmc">PMC5237564</ArticleId><ArticleId IdType="pubmed">28088167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang T.W., Weinstein L. Antiviral activity of isoprinosine in vitro and in vivo. Am. J. Med. Sci. 1973;265:143–146. doi: 10.1097/00000441-197302000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000441-197302000-00005</ArticleId><ArticleId IdType="pubmed">4350802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang T.W., Heel R.C. Ribavirin and inosiplex: A review of their present status in viral diseases. Drugs. 1981;22:111–128. doi: 10.2165/00003495-198122020-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-198122020-00002</ArticleId><ArticleId IdType="pubmed">6167418</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetylpyridinuium Chloride Page in Adis Insight Website.  [(accessed on 4 July 2024)].  Available online:  https://adisinsight.springer.com/drugs/800048807.</Citation></Reference><Reference><Citation>Barrow G.I., Higgins P.G., Al-Nakib W., Smith A.P., Wenham R.B., Tyrrell D.A. The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers. Clin. Exp. Allergy. 1990;20:45–51. doi: 10.1111/j.1365-2222.1990.tb02774.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2222.1990.tb02774.x</ArticleId><ArticleId IdType="pmc">PMC7185334</ArticleId><ArticleId IdType="pubmed">2155688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazdik F., Jahnova E., Horvathova M., Pijak M.R., Gazdikova K. Antiasthmatic effects of nedocromil sodium. Bratisl. Lek. Listy. 2003;104:222–226.</Citation><ArticleIdList><ArticleId IdType="pubmed">15168867</ArticleId></ArticleIdList></Reference><Reference><Citation>Abisheganaden J.A., Avila P.C., Kishiyama J.L., Liu J., Yagi S., Schnurr D., Boushey H.A. Effect of clarithromycin on experimental rhinovirus-16 colds: A randomized, double-blind, controlled trial. Am. J. Med. 2000;108:453–459. doi: 10.1016/S0002-9343(00)00329-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(00)00329-6</ArticleId><ArticleId IdType="pubmed">10781777</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarithromycin page in United Kingdom National Health Service.  [(accessed on 4 July 2024)].  Available online:  https://www.nhs.uk/medicines/clarithromycin/about-clarithromycin/</Citation></Reference><Reference><Citation>Hao W., Bernard K., Patel N., Ulbrandt N., Feng H., Svabek C., Wilson S., Stracener C., Wang K., Suzich J., et al. Infection and propagation of human rhinovirus C in human airway epithelial cells. J. Virol. 2012;86:13524–13532. doi: 10.1128/JVI.02094-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02094-12</ArticleId><ArticleId IdType="pmc">PMC3503113</ArticleId><ArticleId IdType="pubmed">23035218</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta H.A., Sgro J.Y., Palmenberg A.C. Modeling of the human rhinovirus C capsid suggests a novel topography with insights on receptor preference and immunogenicity. Virology. 2014;448:176–184. doi: 10.1016/j.virol.2013.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2013.10.006</ArticleId><ArticleId IdType="pmc">PMC3857591</ArticleId><ArticleId IdType="pubmed">24314648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 Antivirals: Past, Present, and Future. Acta. Pharm. Sin. B. 2022;12:1542–1566. doi: 10.1016/j.apsb.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J., Zhu F., Ma X., Cao Z.W., Li Y.X., Chen Y.Z. Mechanisms of drug combinations: Interaction and network perspectives. Nat. Rev. Drug. Discov. 2009;8:11–128. doi: 10.1038/nrd2683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2683</ArticleId><ArticleId IdType="pubmed">19180105</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Waardenburg R.C., de Jong L.A., van Eijndhoven M.A., Verseyden C., Pluim D., Jansen L.E., Bjornsti M.-A., Schellens J.H.M. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J. Biol. Chem. 2004;29:54502–54509. doi: 10.1074/jbc.M410103200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M410103200</ArticleId><ArticleId IdType="pubmed">15471886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai G.H., Zhang Z., Sirica A.E. Celecoxib acts in a cyloooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced akt inactivation and increased activation of caspase-9 and -3. Mol. Cancer. Ther. 2003;2:262–271.</Citation><ArticleIdList><ArticleId IdType="pubmed">12657721</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottagnoud P., Cottagnoud M., Täuber M.G. Vancomycin acts systematically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin. Antimicrob. Agents Chemother. 2003;47:144–147. doi: 10.1128/AAC.47.1.144-147.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.1.144-147.2003</ArticleId><ArticleId IdType="pmc">PMC148974</ArticleId><ArticleId IdType="pubmed">12499182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Abdelnabi R., Delang L., Froeyen M., Luyten W., Neyts J., Mirabelli C. New class of early-stage enterovirus inhibitors with a novel mechanism of action. Antivir. Res. 2017;147:67–74. doi: 10.1016/j.antiviral.2017.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.10.004</ArticleId><ArticleId IdType="pubmed">28993161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Zusinaite E., Tenson T., Oksenych V., Wang W., Afset J.E., Bjørås M., Kainov D.E. Novel synergistic anti-enteroviral drug combinations. Viruses. 2022;14:1866. doi: 10.3390/v14091866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091866</ArticleId><ArticleId IdType="pmc">PMC9505890</ArticleId><ArticleId IdType="pubmed">36146673</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyanova A., Galabov A.S. Effects of double combinations of enterovirus replication inhibitors against coxsackie B viruses. Acta. Virol. 2021;65:411–419. doi: 10.4149/av_2021_410.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/av_2021_410</ArticleId><ArticleId IdType="pubmed">34978843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaeva-Glomb L., Galabov A.S. Synergistic combinations against the replication in vitro of coxsackievirus B1. Antivir. Res. 2004;62:9–19. doi: 10.1016/j.antiviral.2003.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2003.11.001</ArticleId><ArticleId IdType="pubmed">15026197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonberg-Holm K., Gosser L.B., Kauer J.C. Early alteration of poliovirus in infected cells and its specific inhibition. J. Gen. Virol. 1975;27:329–342. doi: 10.1099/0022-1317-27-3-329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-27-3-329</ArticleId><ArticleId IdType="pubmed">167116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung H.C., Wang H.C., Shih S.R., Teng I.F., Tseng C.P., Hsu J.T. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J. Infect. Dis. 2011;203:1784–1790. doi: 10.1093/infdis/jir174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir174</ArticleId><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden E., Liu H.M., Wang-Chern S.W., Oberste M.S. Anti-poliovirus potency of protease inhibitor AG-7404, and assessment of in vitro potency in combination with antiviral capsid inhibitor compounds. Antiviral. Res. 2013;98:186–191. doi: 10.1016/j.antiviral.2013.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.03.003</ArticleId><ArticleId IdType="pubmed">23499651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li G., Yuan S., Gao Q., Lan K., Altmeyer R., Zou G. In Vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob. Agents Chemother. 2016;60:5357–5367. doi: 10.1128/AAC.01073-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01073-16</ArticleId><ArticleId IdType="pmc">PMC4997834</ArticleId><ArticleId IdType="pubmed">27353263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Yam W.K., Kooi R.J.W., Westman J., Arbrandt G., Chu J.J.H. Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition. Sci. Rep. 2021;11:9719. doi: 10.1038/s41598-021-89271-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89271-8</ArticleId><ArticleId IdType="pmc">PMC8102518</ArticleId><ArticleId IdType="pubmed">33958691</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Jie Q., Shaw N., Li L., Rao Z., Yin Z., Lou Z. Studies on inhibition of proliferation of enterovirus-71 by compound YZ-LY-0. Int. J. Biol. Sci. 2015;11:1337–1347. doi: 10.7150/ijbs.12996.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.12996</ArticleId><ArticleId IdType="pmc">PMC4643065</ArticleId><ArticleId IdType="pubmed">26640412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yang B., Zhai Y., Sun Y., Rao Z. Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C. Antimicrob. Agents Chemother. 2015;59:2636–2646. doi: 10.1128/AAC.00049-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00049-15</ArticleId><ArticleId IdType="pmc">PMC4394787</ArticleId><ArticleId IdType="pubmed">25691647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H., Kim C., Kim D.E., Song J.H., Choi M., Choi K., Kang M., Lee K., Kim H.S., Shin J.S., et al. Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antivir. Res. 2015;124:6. doi: 10.1016/j.antiviral.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.10.011</ArticleId><ArticleId IdType="pubmed">26526589</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassileva-Pencheva R., Galabov A.S. Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice. Antivir. Res. 2010;85:366–372. doi: 10.1016/j.antiviral.2009.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.11.003</ArticleId><ArticleId IdType="pubmed">19900482</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassileva-Pencheva R., Galabov A.S. Effectiveness of the consecutive alternating administration course of a triple antiviral combination in coxsackievirus B3 infections in mice. Drug. Res. 2016;66:639–643. doi: 10.1055/s-0042-112970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0042-112970</ArticleId><ArticleId IdType="pubmed">27552486</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyanova A., Nikolova I., Pürstinger G., Dobrikov G., Dimitrov V., Philipov S., Galabov A.S. Anti-enteroviral triple combination of viral replication inhibitors: Activity against coxsackievirus B1 neuroinfection in mice. Antivir. Chem. Chemother. 2015;24:136–147. doi: 10.1177/2040206616671571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206616671571</ArticleId><ArticleId IdType="pmc">PMC5890508</ArticleId><ArticleId IdType="pubmed">27815331</ArticleId></ArticleIdList></Reference><Reference><Citation>Galabov A.S., Nikolova I., Vassileva-Pencheva R., Stoyanova A. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections. Prilozi (Makedon. Akad. Nauk. Umet. Odd. Med. Nauki.) 2015;36:91–99. doi: 10.1515/prilozi-2015-0057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/prilozi-2015-0057</ArticleId><ArticleId IdType="pubmed">27442375</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyanova A., Nikolova I., Galabov A.S. Effect of consecutive altenarting administration (CAA) of triple anti-enteroviral combination on coxsackievirus B1 neuroinfection in mice. Antivir. Res. 2015;121:138–144. doi: 10.1016/j.antiviral.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.07.004</ArticleId><ArticleId IdType="pubmed">26196747</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyanova A., Galabov A.S. Effect of consecutive alternating administration of a triple combination of anti-enteroviral compounds in mice infected with coxsackievirus B3. Pathog. Dis. 2020;78:ftaa065. doi: 10.1093/femspd/ftaa065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femspd/ftaa065</ArticleId><ArticleId IdType="pubmed">33090201</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyanova A., Galabov A.S. Consecutive alternating administration as an effective anti-coxsackievirus B3 in vivo treatment scheme. Arch. Virol. 2021;166:1869–1875. doi: 10.1007/s00705-021-05057-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-021-05057-3</ArticleId><ArticleId IdType="pubmed">33877422</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaeva L., Galabov A.S. Antiviral effect of combination of enviroxime and disoxaril on coxsackievirus B1 Infection. Acta. Virol. 2000;44:73–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">10989697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Frøysa I.T., Lysvand H., Calitz C., Smura T., Schjelderup Nilsen H.J., Høyer E., Afset J.E., Sridhar A., Wolthers K.C., et al. The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants. Antivir. Res. 2024;224:105842. doi: 10.1016/j.antiviral.2024.105842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2024.105842</ArticleId><ArticleId IdType="pubmed">38417531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Herrington D.T., Coats T.L., Kim K., Cooper E.C., Villano S.A., Liu S., Hudson S., Pevear D.C., Collett M., et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 2003;36:1523–1532. doi: 10.1086/375069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375069</ArticleId><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi R., Baggen J., Mirabelli C., Neyts J. New Drug Development for Known and Emerging Viruses. 1st ed. Wiley-VCH GmbH.; Hoboken, NJ, USA: 2022. Antiviral strategies against (non-polio) picornaviruses.</Citation></Reference><Reference><Citation>Chang Y.K., Chen K.H., Chen K.T. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: A Review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development. Rev. Inst. Med. Trop. Sao Paulo. 2018;60:e70. doi: 10.1590/s1678-9946201860070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1678-9946201860070</ArticleId><ArticleId IdType="pmc">PMC6223252</ArticleId><ArticleId IdType="pubmed">30427405</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm-Hansen C.C., Midgley S.E., Fischer T.K. Global emergence of enterovirus D68: A Systematic review. Lancet Infect. Dis. 2016;16:e64–e75. doi: 10.1016/S1473-3099(15)00543-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00543-5</ArticleId><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston L., Tapparel C. Rhinoviruses and respiratory enteroviruses: Not as simple as ABC. Viruses. 2016;8:16. doi: 10.3390/v8010016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8010016</ArticleId><ArticleId IdType="pmc">PMC4728576</ArticleId><ArticleId IdType="pubmed">26761027</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A., Ekins S., Schmidtke M., Makarov V. Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Eur. J. Med. Chem. 2019;178:606–622. doi: 10.1016/j.ejmech.2019.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.06.008</ArticleId><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Limpens R.W., van der Schaar H.M., Kumar D., Koster A.J., Snijder E.J., van Kuppeveld F.J., Bárcena M. The Transformation of enterovirus replication structures: A Three-dimensional study of single- and double-membrane compartments. mBio. 2011;2:10–1128. doi: 10.1128/mBio.00166-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00166-11</ArticleId><ArticleId IdType="pmc">PMC3187575</ArticleId><ArticleId IdType="pubmed">21972238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff G., Melia C.E., Snijder E.J., Bárcena M. Double-membrane vesicles as platforms for viral replication. Trends Microbiol. 2020;28:1022–1033. doi: 10.1016/j.tim.2020.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7289118</ArticleId><ArticleId IdType="pubmed">32536523</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennemann N.J., Evans A.S., Coyne C.B. Imaging-based reporter systems to define CV-B-induced membrane remodeling in living cells. Viruses. 2020;12:1074. doi: 10.3390/v12101074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12101074</ArticleId><ArticleId IdType="pmc">PMC7600424</ArticleId><ArticleId IdType="pubmed">32992749</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov G.A., Sztul E. Rewiring of cellular membrane homeostasis by picornaviruses. J. Virol. 2014;88:9478–9489. doi: 10.1128/JVI.00922-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00922-14</ArticleId><ArticleId IdType="pmc">PMC4136358</ArticleId><ArticleId IdType="pubmed">24920802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford R.M., Patel N.R., Demenczuk T.M., Watanyar A., Herbetz T., Collet M.S., Pevear D.C. VP1 Sequencing of all human rhinovirus serotypes: Insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J. Virol. 2004;78:3663–3674. doi: 10.1128/JVI.78.7.3663-3674.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.7.3663-3674.2004</ArticleId><ArticleId IdType="pmc">PMC371056</ArticleId><ArticleId IdType="pubmed">15016887</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.L., Lin T.M., Wang S.Y., Wang J.R. The Role of conserved arginine and proline residues in enterovirus VP1 protein. J. Microbiol. Immunol. Infect. 2022;55:590–597. doi: 10.1016/j.jmii.2022.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.01.004</ArticleId><ArticleId IdType="pubmed">35232679</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Peñaranda S., Maher K., Pallansch M.A. Complete genome sequences of all members of the species human enterovirus A. Pt 6J. Gen. Virol. 2004;85:1597–1607. doi: 10.1099/vir.0.79789-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79789-0</ArticleId><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Feil S.C., Hamilton S., Krippner G.Y., Lin B., Luttick A., McConnell D.B., Nearn R., Parker M.W., Ryan J., Stanislawski P.C., et al. An Orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. ACS Med. Chem. Lett. 2012;3:303–307. doi: 10.1021/ml2002955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ml2002955</ArticleId><ArticleId IdType="pmc">PMC4025830</ArticleId><ArticleId IdType="pubmed">24900468</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C.L., Yeo H., Ye H.Q., Liu S.Q., Shang B.D., Gong P., Alonso S., Shi P.Y., Zhang B. Inhibition of enterovirus 71 by adenosine analog NITD008. J. Virol. 2014;88:11915–11923. doi: 10.1128/JVI.01207-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01207-14</ArticleId><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cao L., Zhai Y., Ma J., Nie Q., Li T., Yin Z., Sun Y., Shang L. Inhibition of enterovirus 71 replication by an α-hydroxy-nitrile derivative NK-1.9k. Antivir. Res. 2017;141:91–100. doi: 10.1016/j.antiviral.2017.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.01.002</ArticleId><ArticleId IdType="pubmed">28063993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.H., Wang K., Zhao K., Hua S.C., Du J. The Structure, function, and mechanisms of action of enterovirus non-structural protein 2C. Front. Microbiol. 2020;11:615965. doi: 10.3389/fmicb.2020.615965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.615965</ArticleId><ArticleId IdType="pmc">PMC7767853</ArticleId><ArticleId IdType="pubmed">33381104</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser L.J., Langereis M.A., Rabouw H.H., Wahedi M., Muntjewerff E.M., de Groot R.J., van Kuppeveld F.J.M. Essential role of enterovirus 2A protease in counteracting stress granule formation and the induction of type I interferon. J. Virol. 2019;93:10–1128. doi: 10.1128/JVI.00222-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00222-19</ArticleId><ArticleId IdType="pmc">PMC6498061</ArticleId><ArticleId IdType="pubmed">30867299</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Wu S., Xiao T., Li Y., Su Z., Wei W., Hao F., Hu G., Lin F., Chen X., et al. Design, synthesis, and evaluation of a novel macrocyclic anti-EV71 agent. Bioorg. Med. Chem. 2020;28:115551. doi: 10.1016/j.bmc.2020.115551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2020.115551</ArticleId><ArticleId IdType="pubmed">32503695</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutschmann-Olek K.M., Yue W.W., Bezerra G.A., Skern T. Defining substrate selection by rhinoviral 2A proteinase through its crystal structure with the inhibitor zVAM.fmk. Virology. 2021;562:128–141. doi: 10.1016/j.virol.2021.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2021.07.008</ArticleId><ArticleId IdType="pubmed">34315103</ArticleId></ArticleIdList></Reference><Reference><Citation>El Kazzi P., Yaacoub C., Fajloun Z., Vanelle P., Decoly E., Coutard B., Barral K. 2C Protein of enterovirus: Key protein of viral replication and antiviral target. Virologie. 2023;27:35–49. doi: 10.1684/vir.2023.1002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/vir.2023.1002</ArticleId><ArticleId IdType="pubmed">37476987</ArticleId></ArticleIdList></Reference><Reference><Citation>Doppalapudi S., Jain A., Khan W., Domb A.J. Biodegradable Polymers—An Overview. Polym. Adv. Technol. 2014;25:427–435. doi: 10.1002/pat.3305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pat.3305</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G.H., Luo Y.J., Wu X.Y., Si B.Y., Lin L., Zhu Q.Y. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol. J. 2010;7:106. doi: 10.1186/1743-422X-7-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-106</ArticleId><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Xu C., Dai W., Wang Y., Liu Z., Zhang X., Wang X., Wang H., Gong S., Cong Y., et al. Functional and structural characterization of a two-MAb cocktail for delayed treatment of enterovirus D68 infections. Nat. Commun. 2021;12:2904. doi: 10.1038/s41467-021-23199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23199-5</ArticleId><ArticleId IdType="pmc">PMC8131599</ArticleId><ArticleId IdType="pubmed">34006855</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Loon A.M., Cleator G.C., Ras A. External quality assessment of enterovirus detection and typing. European Union Concerted Action on Virus Meningitis and Encephalitis. Bull. World Health Organ. 1999;77:217–223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2557629</ArticleId><ArticleId IdType="pubmed">10212511</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chan Y.F., Sim K.M., Tan E.L., Poh C.L. Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. PLoS ONE. 2012;7:e34589. doi: 10.1371/journal.pone.0034589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034589</ArticleId><ArticleId IdType="pmc">PMC3341398</ArticleId><ArticleId IdType="pubmed">22563456</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H.R., Poh C.L., Fecondo J., Grollo L. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res. 2012;169:22–29. doi: 10.1016/j.virusres.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Jiang X., He S., Jiang H., Feng F., Liu W., Qu W., Sun H. Rational design of multitarget-directed ligands: Strategies and emerging paradigms. J. Med. Chem. 2019;62:8881–8914. doi: 10.1021/acs.jmedchem.9b00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b00017</ArticleId><ArticleId IdType="pubmed">31082225</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Li X., Liu F., Li S., Shi D. Rational multitargeted drug design strategy from the perspective of a medecinal chemist. J. Med. Chem. 2021;64:10581–10605. doi: 10.1021/acs.jmedchem.1c00683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00683</ArticleId><ArticleId IdType="pubmed">34313432</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves S., Resta S., Santos M.A. Design, synthesis, and in vitro evaluation of hydroxybenzimidazole-donepezil analogues as multitarget-directed ligands for the treatment of Alzheimer’s disease. Molecules. 2020;25:985. doi: 10.3390/molecules25040985.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25040985</ArticleId><ArticleId IdType="pmc">PMC7070709</ArticleId><ArticleId IdType="pubmed">32098407</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdolmaleki A., Ghasemi J.B. Dual-acting of hybrid compounds—A New dawn in the discovery of multi-target drugs: Lead generation approaches. Curr. Top. Med. Chem. 2017;17:1096–1114. doi: 10.2174/1568026616666160927151144.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026616666160927151144</ArticleId><ArticleId IdType="pubmed">27697056</ArticleId></ArticleIdList></Reference><Reference><Citation>Csermely P., Agoston V., Pongor S. The Efficacy of multi-target drugs: The Network approach might help drug design. Trends Pharmacol. Sci. 2005;26:178–182. doi: 10.1016/j.tips.2005.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2005.02.007</ArticleId><ArticleId IdType="pubmed">15808341</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls L.N., Eadens M., Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist. 2011;16:566–578. doi: 10.1634/theoncologist.2010-0408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2010-0408</ArticleId><ArticleId IdType="pmc">PMC3228195</ArticleId><ArticleId IdType="pubmed">21521831</ArticleId></ArticleIdList></Reference><Reference><Citation>Boran A.D., Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug. Discov. Devel. 2010;13:297–309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068535</ArticleId><ArticleId IdType="pubmed">20443163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram N., Mirza M.U., Vanmeert M., Froeyen M., Salo-Ahen O.M.H., Tahir M., Qazi A., Ahmad S. Inhibition of oncogenic kinases: An in vitro validated computational approach identified potential multi-target anticancer compounds. Biomolecules. 2019;9:124. doi: 10.3390/biom9040124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom9040124</ArticleId><ArticleId IdType="pmc">PMC6523505</ArticleId><ArticleId IdType="pubmed">30925835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N., Gupta S., Chand Yadav T., Pruthi V., Kumar Varadwaj P., Goel N. Extrapolation of phenolic compounds as multi-target agents against cancer and inflammation. J. Biomol. Struct. Dyn. 2019;37:2355–2369. doi: 10.1080/07391102.2018.1481457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2018.1481457</ArticleId><ArticleId IdType="pubmed">30047324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunil D., Kamath P.R. Multi-target directed indole based hybrid molecules in cancer therapy: An Up-to-date evidence-based review. Curr. Top. Med. Chem. 2017;17:959–985. doi: 10.2174/1568026616666160927150839.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026616666160927150839</ArticleId><ArticleId IdType="pubmed">27697057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sbaraglini M.L., Talevi A. Hybrid compounds as anti-infective agents. Curr. Top. Med. Chem. 2017;17:1080–1095. doi: 10.2174/1568026616666160927160912.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026616666160927160912</ArticleId><ArticleId IdType="pubmed">27697047</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik B., Gupta N., Ojha R., Singh S., Prajapati V.K., Prusty D. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. Int. J. Biol. Macromol. 2020;160:1–17. doi: 10.1016/j.ijbiomac.2020.05.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.05.184</ArticleId><ArticleId IdType="pmc">PMC7250083</ArticleId><ArticleId IdType="pubmed">32470577</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassini S., Sun L., Lanko K., Crespan E., Langron E., Falchi F., Kissova M., Armijos-Rivera J.I., Delang L., Mirabelli C., et al. Discovery of multi-target agents active as broad-spectrum antivirals and correctors of cystic fibrosis transmembrane conductance regulator (CFTR) for associated pulmonary diseases. J. Med. Chem. 2017;60:1400–1416. doi: 10.1021/acs.jmedchem.6b01521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01521</ArticleId><ArticleId IdType="pubmed">28122178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambure P., Bhat J., Puzyn T., Roy K. Identifying natural compounds as multi-target-directed ligands against Alzheimer’s disease: An in Silico approach. J. Biomol. Struct. Dyn. 2019;37:1282–1306. doi: 10.1080/07391102.2018.1456975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2018.1456975</ArticleId><ArticleId IdType="pubmed">29578387</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotti L., Mendonca Junior F.J., Ishiki H.M., Ribeiro F.F., Singla R.K., Barbosa Filho J.M., Da Silva M.S., Scotti M.T. Docking studies for multi-target drugs. Curr. Drug. Targets. 2017;18:592–604. doi: 10.2174/1389450116666150825111818.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450116666150825111818</ArticleId><ArticleId IdType="pubmed">26302806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>